Skip to main content
. 2019 Nov 25;35(2):313–319. doi: 10.1111/jocs.14376

Table 1.

Baseline demographics for each treatment group

Measure All CP HM P value
Age, y a 63.7 ± 11.7 (57.8, 71.2) 62.6 ± 11.4 (57.8, 71.1) 64.9 ± 12.1 (58.0, 73.7) .323
Gender b .120
Male 81/105 (77.1%) 37/53 (69.8%) 44/52 (84.6%)
Female 24/105 (22.9%) 16/53 (30.2%) 8/52 (15.4%)
Ethnicity b .083
Hispanic or Latino 10/105 (9.5%) 8/53 (15.1%) 2/52 (3.8%)
Not Hispanic or Latino 94/105 (89.5%) 44/53 (83.0%) 50/52 (96.2%)
Missing 1/105 (1.0%) 1/53 (1.9%) 0 (0.0%)
Race b .480
Caucasian 49/105 (46.7%) 27/53 (50.9%) 22/52 (42.3%)
African American 10/105 (9.5%) 4/53 (7.5%) 6/52 (11.5%)
American Indian or Alaska native 0/105 (0.0%) 0/53 (0.0%) 0/52 (0.0%)
Asian 24/105 (22.9%) 9/53 (17.0%) 15/52 (28.8%)
Native Hawaiian or other Pacific Islander 13/105 (12.4%) 7/53 (13.2%) 6/52 (11.5%)
Other 9/105 (8.6%) 6/53 (11.3%) 3/52 (5.8%)
BMI, kg/m2 a 31.6 ± 30.5 (25.0, 31.6) 28.8 ± 6.6 (24.0, 31.9) 34.3 ± 42.8 (25.1, 30.6) .364

Abbreviations: CP, combination powder; HM, hemostatic matrix.

a

Reported as mean ± standard deviation (p25, p75).

b

Reported as n/N (%).